SSGJ-707 + carboplatin + paclitaxel

SSGJ-707 + carboplatin + paclitaxel is an investigational combination therapy for cancer, comprising SSGJ-707—a bispecific antibody targeting PD-1 (programmed cell death protein 1) and VEGF (vascular endothelial growth factor)—with the chemotherapeutic agents carboplatin and paclitaxel. SSGJ-707 is designed to simultaneously block PD-1-mediated immune checkpoint inhibition and VEGF-dependent angiogenesis, aiming to boost anti-tumor immune responses while inhibiting tumor blood vessel formation. This combination is under clinical investigation for advanced solid tumors including metastatic colorectal cancer and non-small cell lung cancer, in first-line and later treatment settings[1][3][5][7].